CEP Milestone Achieved

In February 2026 Linnea's Cannabidiol Isolate has successfully obtained the CEP certification (Certificate of Suitability to the European Pharmacopoeia).

In February 2026 Linnea's Cannabidiol Isolate has successfully obtained the CEP certification (Certificate of Suitability to the European Pharmacopoeia). This certification attests that the quality of an active pharmaceutical ingredient (API) is adequately controlled by the monographs of the European Pharmacopoeia, ensuring its safety, quality and conformity for use in medicinal products in Europe. In short: it is an independent validation of consistency, safety, and regulatory compliance for the European market. This consequently simplifies the marketing authorization (MA) process for new medicines, as a detailed evaluation of the active substance by regulatory authorities is not required. A big thank-you to all those who made this possible — and to our customers who trust us to deliver premium-quality cannabinoids.On to the next chapter of quality, transparency, and global compliance.